StreetAlpha
Grace Therapeutics, Inc. · Earnings

GRCE Earnings Results and History

Latest: Q2 2027From SEC 8-K, 10-Q and 10-K filingsNext report: Feb 15, 2027

Grace Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← GRCE stock page

Q2 2027 result
Results are out
  • EPS−$0.11
  • Revenue–

Filed ยท Press release

EPS beat rateFree accountlast 6 reports
Avg move afterFree accountnext day, after each report

Key takeaways

from the press release
  • Net loss was $2.1M, or $0.11 per share, up from $0.9M a year ago, mainly because a $1.4M warrant gain last year did not recur.
  • R&D rose to $0.9M from $0.6M on dual source manufacturing work and required nonclinical studies for GTx-104.
3 more takeaways with a free account.Create free account

EPS by quarter

GAAP diluted, 12 quarters
Dec 2023: EPS -$0.21-0.21Dec '23Mar 2024: EPS -$0.26-0.26Mar '24Jun 2024: EPS -$0.24-0.24Jun '24Sep 2024: EPS -$0.30-0.30Sep '24Dec 2024: EPS -$0.36-0.36Dec '24Mar 2025: EPS $0.100.10Mar '25Jun 2025: EPS -$0.21-0.21Jun '25Sep 2025: EPS -$0.06-0.06Sep '25Dec 2025: EPS -$0.14-0.14Dec '25Mar 2026: EPS -$0.06-0.06Mar '26Jun 2026: EPS -$0.91-0.91Jun '26Sep 2026: EPS -$0.11-0.11Sep '26

Quarter by quarter

from 10-Q and 10-K filings
Quarter endedRevenueGrowthOp marginNet incomeEPS
Sep 2026–––−$2.1M−$0.11
Jun 2026–––−$15.8M−$0.91
Mar 2026–––−$1.2M−$0.06
Dec 2025–––−$2.3M−$0.14
Create a free account to see all 12 quarters, or sign in.

EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.

Reports and price reactions

last 7 reports
How GRCE moved after each of its last 7 reports, the move options priced in, and StreetAlpha's call. Free account.Create free account

Year by year

fiscal years, from 10-K filings
Year endedRevenueGrowthOp marginNet incomeEPS
Mar 31, 2026–––−$7.8M−$0.47
Mar 31, 2025–––−$9.6M−$0.79
Mar 31, 2024–––−$12.9M−$1.35
Mar 31, 2023–––−$42.4M−$5.71
Mar 31, 2022–––−$9.8M−$0.27

Filings and dates

SEC EDGAR
  • Feb 15, 2027Next earnings reportexpected
  • Nov 12, 2026Earnings release, Q2 20278-K Press release
  • Nov 12, 2026Quarterly report10-Q All filings

Also see GRCE institutional ownership and the earnings calendar.

GRCE earnings FAQ

What were GRCE's latest earnings?

For Q2 2027 Grace Therapeutics, Inc. reported, GAAP EPS of -$0.11. The results were filed with the SEC on Nov 12, 2026.

When is GRCE's next earnings date?

Grace Therapeutics, Inc. is expected to report on Feb 15, 2027. Dates can move until the company confirms them.

Is GRCE's revenue growing?

In the quarter ended Sep 30, 2026 revenue was . The table on this page shows every quarter from the company's 10-Q and 10-K filings.

Where do these numbers come from?

Results, guidance and financials come from Grace Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.